More on ELVN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Enliven Therapeutics, Inc (NQ:ELVN)
Delayed: 37.32 -2.01 (5.11%)
Prev. Close $39.33  
Open$39.33 
52 Wk High$ 
52 Wk Low$ 
Day High$39.47 
Day Low$36.96 
P/E N/A  
EPS$ 
Volume1,188,446 

Friends, Peers and Foes (?): ALLO, CHRS, ONCY, PYXS, MAZE (more...)

Oct 16, 2026 04:43 PM Form 4 Enliven Therapeutics, For: Oct 14 Filed by: BALL KRISTINE M
Oct 16, 2026 04:41 PM Form 3 Enliven Therapeutics, For: Oct 14 Filed by: BALL KRISTINE M
Oct 14, 2026 04:39 PM Form 8-K Enliven Therapeutics, For: Oct 14
Oct 14, 2026 04:30 PM Enliven Therapeutics adds Kristine Ball to its board of directors
Oct 14, 2026 04:30 PM Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Oct 8, 2026 06:55 AM Guggenheim Reiterates Buy Rating on Enliven Therapeutics (ELVN)
Oct 6, 2026 04:05 PM Enliven gets FDA alignment on Phase 3 CML trial design
Oct 6, 2026 04:05 PM Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Oct 5, 2026 04:57 PM Form 4 Enliven Therapeutics, For: Oct 01 Filed by: Garland J. Scott
Oct 2, 2026 02:40 AM Morgan Stanley Starts Enliven Therapeutics (ELVN) at Overweight
View All Articles

Entities mentioned with ELVN

View All Entities